User login
Patients who develop HCV infections after liver transplant may respond to a 24-week course of sofosbuvir and ribavirin, Dr. Michael Charlton, of the Mayo Clinic in Rochester, Minn., and his colleagues reported.
The researchers enrolled and treated 40 liver transplant patients with compensated recurrent HCV infection of any genotype; 83% had HCV genotype 1, 40% had cirrhosis (based on biopsy), and 88% had been previously treated with interferon. All patients received 24 weeks of sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily, which was adjusted according to creatinine clearance and hemoglobin values, the researchers said in the January 2015 issue of Gastroenterology.
After 12 weeks, 28 of 40 had a sustained virologic response (70%; 90% confidence interval: 56%−82%). Relapse accounted for all cases of virologic failure. No patients had detectable viral resistance during or after treatment.
Click here to read the study: http://www.ncbi.nlm.nih.gov/pubmed/25304641
Patients who develop HCV infections after liver transplant may respond to a 24-week course of sofosbuvir and ribavirin, Dr. Michael Charlton, of the Mayo Clinic in Rochester, Minn., and his colleagues reported.
The researchers enrolled and treated 40 liver transplant patients with compensated recurrent HCV infection of any genotype; 83% had HCV genotype 1, 40% had cirrhosis (based on biopsy), and 88% had been previously treated with interferon. All patients received 24 weeks of sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily, which was adjusted according to creatinine clearance and hemoglobin values, the researchers said in the January 2015 issue of Gastroenterology.
After 12 weeks, 28 of 40 had a sustained virologic response (70%; 90% confidence interval: 56%−82%). Relapse accounted for all cases of virologic failure. No patients had detectable viral resistance during or after treatment.
Click here to read the study: http://www.ncbi.nlm.nih.gov/pubmed/25304641
Patients who develop HCV infections after liver transplant may respond to a 24-week course of sofosbuvir and ribavirin, Dr. Michael Charlton, of the Mayo Clinic in Rochester, Minn., and his colleagues reported.
The researchers enrolled and treated 40 liver transplant patients with compensated recurrent HCV infection of any genotype; 83% had HCV genotype 1, 40% had cirrhosis (based on biopsy), and 88% had been previously treated with interferon. All patients received 24 weeks of sofosbuvir 400 mg daily and ribavirin starting at 400 mg daily, which was adjusted according to creatinine clearance and hemoglobin values, the researchers said in the January 2015 issue of Gastroenterology.
After 12 weeks, 28 of 40 had a sustained virologic response (70%; 90% confidence interval: 56%−82%). Relapse accounted for all cases of virologic failure. No patients had detectable viral resistance during or after treatment.
Click here to read the study: http://www.ncbi.nlm.nih.gov/pubmed/25304641